Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead
N. G. R. Dayan Elshan, Karen C. Wolff, Frank O. Weiss, Sourav Ghorai, Gennadii A. Grabovyi, Katy Wilson, Laura Riva, Ashley K. Woods, James R. Pedroarena, Armen Nazarian, Yuyin Liu, Wrickban Mazumdar, Lirui Song, Neechi Okwor, Jacqueline Malvin, , Arnab K. Chatterjee
This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.
Viruses · Jul 26, 2026Peer-reviewedPharmacology & Toxicology